查看文章

Purpose: Delaying the natural progression of pathologic macular aging to maintain sight for the large numbers of individuals affected by age related macular degeneration (AMD). The goal of this in vivo, pre-clinical study is to optimize pharmacodelivery to enhance macular pharmacotherapies by comparing the efficacy of microneedle delivered suprachoroidal (SC) pazopanib to intravitreal (Ivit) delivery of pazopanib, bevacizumab, or a fusion protein hI-con-1 versus controls on the growth of type 2 choroidal neovascularization (CNV) in the porcine model.

Methods: Forty-one pigs were injected either on the day of CNV induction or post-induction day# 14 (hI-con1) with either 2.5 mg Ivit bevacizumab (n= 9), 1 mg pazopanib (n= 9), 300 Ivit mg hI-con1 (n= 4), or 1 mg SC pazopanib (n= 9), versus 10 vehicle controls (3 SC+ 7 Ivit= 10). Pigs were euthanized at postoperative week 2 (11), 3 (8), 4 (11), and 8 (11). Eyes were …